Table 1

Baseline Data

Total
(N = 100)
Esmolol Group
(n = 50)
Placebo Group
(n = 50)
p Value
Age, yrs59.7 ± 11.857.9 ± 11.261.4 ± 12.20.14
Male77 (77)41 (82)36 (72)0.34
Body mass index, kg/m226.4 ± 4.026.6 ± 3.826.1 ± 4.10.51
Known coronary artery disease (%)12 (12)5 (10)7 (14)0.76
Previous myocardial infarction (%)7 (7)3 (6)4 (8)1.00
Previous coronary intervention (%)7 (7)2 (4)5 (10)0.44
Hypertension54 (54)27 (54)27 (54)1.0
Smoking52 (52)30 (60)22 (44)0.16
Dyslipidemia29 (29)13 (26)16 (32)0.66
Diabetes mellitus12 (12)6 (12)6 (12)1.0
eGFR (ml/min)90.7 ± 23.691.5 ± 21.089.8 ± 26.00.71
Infarct-related artery
 LAD43 (43.4)17 (34)26 (53.1)0.134
 RCX10 (10.1)5 (10)5 (10.2)
 RCA46 (46.5)28 (56)18 (36.7)
BARI index (%)38.93 ± 5.3838.77 ± 5.5739.09 ± 5.210.35
APPROACH score (%)41.07 ± 4.4141.23 ± 4.5640.91 ± 4.290.40
SBP at baseline, mm Hg137.8 ± 21.6137.4 ± 20.7138.2 ± 22.60.87
Heart rate at baseline, beats/min79.4 ± 14.679.5 ± 14.779.4 ± 14.60.97

Values are mean ± SD or n (%).

APPROACH = Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease; BARI = Bypass Angioplasty Revascularization Investigation Myocardial Jeopardy Index; eGFR = estimated glomerular filtration rate; LAD = left anterior descending; RCA = right coronary artery; RCX = ramus circumflexus; SBP = systolic blood pressure.

  • Student t test.

  • Fisher exact test.

  • One patient with infarct related to LAD and RCX excluded.